RARE - Ultragenyx Pharmaceutical Q2 2022 Earnings Preview
- Ultragenyx Pharmaceutical ( NASDAQ: RARE ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close.
- The consensus EPS Estimate is -$1.64 and the consensus Revenue Estimate is $87.33M (+0.4% Y/Y).
- Over the last 3 months, EPS estimates have seen 1 upward revision and 3 downward. Revenue estimates have seen 3 upward revisions and 9 downward.
For further details see:
Ultragenyx Pharmaceutical Q2 2022 Earnings Preview